Immunotherapy led to statistically longer PFS across all tested subgroups of anti‐PD‐1 drug (HR 0.71, 95% CI 0.58‐0.88) and anti‐PD‐L1 drug (HR 0.64, 95% CI 0.56‐0.74), monotherapy (HR 0.72, 95% CI 0.56‐0.92) and combination therapy (HR 0.64, 95% CI 0.57‐0.71) in male NSCLC patients. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.